Skip to main content

4D Molecular Therapeutics, Inc.

corporate_fare Company Profile

4D Molecular Therapeutics, Inc.

FDMT·NASDAQ·Life Sciences·CIK 0001650648

4D Molecular Therapeutics is a late-stage biotechnology company developing durable and disease-targeted therapies. The company's products are developed using customized and evolved adeno-associated virus ("AAV") vectors, which are invented from its proprietary Therapeutic Vector Evolution ("TVE") platform. TVE is designed to create vectors that overcome the limitations of conventional AAV vectors by applying directed evolution principles in non-human primate ("NHP") models. This process selects vectors that target tissues of diseases with high unmet need using routine and local administration routes. The company focuses on clinical-stage product candidates for retina and lung conditions, utilizing vectors invented with TVE. Its lead product candidate, 4D-150, uses the proprietary R100 vector and a transgene encoding anti-VEGF biologics: aflibercept (targeting VEGF-A, VEGF-B, and placental growth factor) and an RNA interference (RNAi) approach targeting VEGF-C. 4D-150 is being developed to treat wet age-related macular degeneration ("wet AMD") and diabetic macular edema ("DME"). Another pipeline program, 4D-710, is a genetic medicine designed to deliver and express the cystic fibrosis transmembrane conductance regulator ("CFTR") transgene in the lungs of people with cystic fibrosis ("CF") and is currently in Phase 2 development.

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 18 items for FDMT at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-12, rated 7/10. Across its 18 most recent items scored 7 or higher, the top rating is 9/10, with 13 rated 8 or above. Recent SEC coverage for FDMT spans 8-K, S-3, 10-Q, DEF 14A.

Recent high-impact activity:

  • Q3 Loss Widens to $78M, Missing Estimates as Operating Expenses Hit $85M
  • 4DMT Reports 2-Year SPECTRA Data and Details 4SIGHT Phase 3 DME Trial Design
  • 4DMT Launches Phase 3 4SIGHT Trial for DME, Reports Strong 2-Year SPECTRA Data
  • 4DMT Reports Q2 2026 Results, Extends Cash Runway to H2 2028
  • 4D-150 Delivers Durable Two-Year Wet AMD Efficacy, Driving 87% Treatment Burden Reduction in Key Subgroup

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$85.21M
Net Income
-$140.11M
Diluted EPS
-$2.42
Op. Cash Flow
-$109.08M
Free Cash Flow
-$109.62M
Operating Income
-$159.55M
Cash & Equivalents
$60.24M
Debt / Equity
0.00×
Net Margin
-164.4%
Shares Outstanding
57.61M sh
Source: 10-K · filed 2026-03-18 · accession 0001193125-26-114075

Short Interest & Short Volume

10.43 days to cover

FINRA reported short interest of 10,897,478 shares in FDMT as of the October 30, 2026 settlement, a 5.5% decrease from the prior period — about 10.4 days to cover at its recent average daily volume. On November 20, 2026, 53.1% of FDMT volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)10,897,478 shares as of October 30, 2026
Change vs prior period▼ 5.5%
Days to cover10.43 at avg daily volume of 1,045,170
Daily short volume (FINRA facilities)53.1% of 162,601 shares on November 20, 2026
5-day average short volume48.1%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with F →
$10.23
52-week range · as of 2026-09-28 $6.96 – $16.93
Market cap
$576.76M
Volume
691K (0.7× avg)
3-mo avg 939.4K
Live data · 2026-11-22 03:53 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed FDMT - Latest Insights

FDMT
Nov 12, 2026, 4:06 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $12.05
Real-time Price: $10.23 info
Change: -$1.82 (-15%) info
Market Cap: $576.761M info
FDMT
Sep 28, 2026, 8:05 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $14.30
Real-time Price: $10.23 info
Change: -$4.07 (-28%) info
Market Cap: $576.761M info
FDMT
Sep 28, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $14.30
Real-time Price: $10.23 info
Change: -$4.07 (-28%) info
Market Cap: $576.761M info
FDMT
Aug 13, 2026, 4:06 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $11.32
Real-time Price: $10.23 info
Change: -$1.09 (-10%) info
Market Cap: $576.761M info
FDMT
Jul 20, 2026, 8:30 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $11.30
Real-time Price: $10.23 info
Change: -$1.07 (-9%) info
Market Cap: $576.761M info
FDMT
Jul 18, 2026, 3:15 PM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $10.29
Real-time Price: $10.23 info
Change: -$0.062 (-0.60%) info
Market Cap: $576.761M info
FDMT
Jun 29, 2026, 8:05 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $11.37
Real-time Price: $10.23 info
Change: -$1.14 (-10%) info
Market Cap: $576.761M info
FDMT
Jun 29, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $11.37
Real-time Price: $10.23 info
Change: -$1.14 (-10%) info
Market Cap: $576.761M info
FDMT
May 07, 2026, 4:57 PM EDT
Filing Type: S-3
Importance Score:
8
Price at Filing: $9.80
Real-time Price: $10.23 info
Change: +$0.430 (+4%) info
Market Cap: $576.761M info
FDMT
May 07, 2026, 4:32 PM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $9.80
Real-time Price: $10.23 info
Change: +$0.430 (+4%) info
Market Cap: $576.761M info
FDMT
May 07, 2026, 4:13 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $9.80
Real-time Price: $10.23 info
Change: +$0.430 (+4%) info
Market Cap: $576.761M info
FDMT
May 07, 2026, 4:10 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $9.80
Real-time Price: $10.23 info
Change: +$0.430 (+4%) info
Market Cap: $576.761M info
FDMT
Apr 28, 2026, 4:05 PM EDT
Filing Type: DEF 14A
Importance Score:
7
Price at Filing: $9.42
Real-time Price: $10.23 info
Change: +$0.810 (+9%) info
Market Cap: $576.761M info
FDMT
Mar 18, 2026, 4:29 PM EDT
Filing Type: 10-K
Importance Score:
9
Price at Filing: $8.70
Real-time Price: $10.23 info
Change: +$1.53 (+18%) info
Market Cap: $576.761M info
FDMT
Mar 18, 2026, 4:09 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $8.94
Real-time Price: $10.23 info
Change: +$1.29 (+14%) info
Market Cap: $576.761M info
FDMT
Mar 18, 2026, 4:05 PM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $8.98
Real-time Price: $10.23 info
Change: +$1.25 (+14%) info
Market Cap: $576.761M info
FDMT
Jan 26, 2026, 4:05 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $7.97
Real-time Price: $10.23 info
Change: +$2.26 (+28%) info
Market Cap: $576.761M info
FDMT
Jan 07, 2026, 8:05 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $7.55
Real-time Price: $10.23 info
Change: +$2.68 (+36%) info
Market Cap: $576.761M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets